Viewing Study NCT01628068


Ignite Creation Date: 2025-12-24 @ 5:47 PM
Ignite Modification Date: 2025-12-29 @ 6:50 PM
Study NCT ID: NCT01628068
Status: UNKNOWN
Last Update Posted: 2012-06-26
First Post: 2012-06-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: ELIGIBLE (Efficacy of Left atrIal Appendage Closure After GastroIntestinal BLEeding)
Sponsor: Hospital Clinic of Barcelona
Organization:

Study Overview

Official Title: Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding
Status: UNKNOWN
Status Verified Date: 2012-06
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ELIGIBLE
Brief Summary: Patients with atrial fibrillation requiring anticoagulation treatment are at high risk of gastrointestinal bleeding. The investigators propose the percutaneous stop the oral anticoagulation and closure of the left atrial appendage with the Amplatzer ® system in patients receiving anticoagulant therapy for atrial fibrillation without associated valvular heart disease, to reduce significantly the risk of stroke while minimizing the risk of bleeding in a group of patients with high risk for both events.

ELIGIBLE trial(Left atrial appendage Efficacy of GastroIntestinal Bleeding after closure) is a prospective, multicentric and randomized (2 to 1) trial, comparing percutaneous closure of atrial appendage left versus standard treatment with oral anticoagulants in patients with history of gastrointestinal bleeding and high embolic risk.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
Estudio ELIGIBLE OTHER Fundació Clínic View